The results of this study show that targeting NFkB with PIs such as carfilzomib in combination with fulvestrant in CTCs from ER+/HER2− breast cancer might offer the opportunity to block metastatic progression at a subclinical stage before metastases appear. The gene discussed is ESR1; the disease is breast cancer.